Form 4 for ABT Abbott Laboratories
Accepted 2026-01-26 00:00:00 ET · period of report 2026-01-23 · accession 0001612571-26-000002 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| I | 2026-01-26 | 2026-01-23 | ABT | Ford Robert B | COB AND CEO, Dir | P - Purchase | $107.13 | +18.8K | 216.2K | +10% | +$2.01M |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common shares without par value | 2026-01-23 | P | A | 18,800 | $107.13 | 216,203 | I Ford Family Trust | — | — | (F1) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $106.735 to $107.485, inclusive. The reporting person undertakes to provide to Abbott Laboratories, any security holder of Abbott Laboratories, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. (F2) Held in the Ford Family Trust DTD June 2, 2014. The reporting person is co-trustee of the trust. |